BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 10901374)

  • 1. Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha.
    Braybrooke JP; Propper DJ; O'Byrne KJ; Koukourakis MI; Patterson AV; Houlbrook S; Love SD; Varcoe S; Taylor M; Ganesan TS; Talbot DC; Harris AL
    Br J Cancer; 2000 Jul; 83(2):219-24. PubMed ID: 10901374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial.
    Wolff K; Wein A; Reulbach U; Männlein G; Brückl V; Meier C; Ostermeier N; Schwab SA; Horbach T; Hohenberger W; Hahn EG; Boxberger F
    Anticancer Drugs; 2009 Mar; 20(3):165-73. PubMed ID: 19125117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Influence on 5-fluorouracil metabolism by combination of interferon-alpha and 5-fluorouracil against human hepatocellular carcinoma xenografts].
    Jin CD; Yamamoto T; Nakamura M; Arai I; Kishin R; Xing X; Nagano H; Dono K; Umeshita K; Nakamori S; Sakon M; Monden M
    Gan To Kagaku Ryoho; 2004 Oct; 31(10):1511-5. PubMed ID: 15508442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols.
    Pacheco AV; Rasila K; Lee SJ; Rabinowitz I; Elias L; Lee FC; Verschraegen CF
    Urol Oncol; 2008; 26(6):610-5. PubMed ID: 18367103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Interferon-alpha upregulates thymidine phosphorylase expression via JAK-STAT transcriptional activation and mRNA stabilization in human hepatocellular carcinoma SMMC-7721 cells].
    Xiao YS; Zhou J; Fan J; Sun QM; Zhao Y; Sun RX; Liu YK; Tang ZY
    Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):444-7. PubMed ID: 19024520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with interferon-alpha in renal cell carcinoma cell lines.
    Ikemoto S; Sugimura K; Yoshida N; Kuratsukuri K; Wada S; Nakatani T
    Urol Int; 2004; 73(4):348-53. PubMed ID: 15604581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
    O'connor T; Rustum Y; Levine E; Creaven P
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000.
    Gez E; Rubinov R; Gaitini D; Meretyk S; Best LA; Native O; Stein A; Erlich N; Beny A; Zidan J; Haim N; Kuten A
    Cancer; 2002 Oct; 95(8):1644-9. PubMed ID: 12365011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy.
    Sundar S; Symonds RP; Decatris MP; Kumar DM; Osman A; Vasanthan S; O'byrne KJ
    Gynecol Oncol; 2004 Aug; 94(2):502-8. PubMed ID: 15297195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
    Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
    Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.
    Sobrero A; Guglielmi A; Cirillo M; Recaldin E; Frassineti GL; Aschele C; Ravaioli A; Testore P; Caroti C; Gallo L; Pessi MA; Cortesi E; Turci D; Grossi F; Labianca R
    Br J Cancer; 2001 Apr; 84(8):1023-8. PubMed ID: 11308248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic arterial chemotherapy with oxaliplatin, folinic acid and 5-fluorouracil in pre-treated patients with liver metastases from colorectal cancer.
    Del Freo A; Fiorentini G; Sanguinetti F; Muttini MP; Pennucci C; Mambrini A; Pacetti P; Della Seta R; Lombardi M; Torri T; Cantore M
    In Vivo; 2006; 20(6A):743-6. PubMed ID: 17203759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palliative second-line treatment with weekly high-dose 5-fluorouracil as 24-hour infusion and folinic acid (AIO) plus oxaliplatin after pre-treatment with the AIO-regimen in colorectal cancer (CRC).
    Link K; Happich K; Schirner I; Jüngert B; Brückl V; Männlein G; Brückl WM; Merkel S; Göhl J; Hohenberger W; Hahn EG; Wein A
    Anticancer Res; 2004; 24(1):385-91. PubMed ID: 15015625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymidine phosphorylase expression in invasive carcinoma: correlations with clinicopathologic variables and in vitro chemosensitivity to 5-fluorouracil.
    Yang Q; Shan L; Yoshimura G; Taniguchi E; Suzuma T; Nakamura Y; Nakamura M; Utsunomiya H; Tang W; Sakurai T; Kakudo K
    Anticancer Res; 1999; 19(6C):5543-6. PubMed ID: 10697613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer.
    Luo HY; Xu RH; Zhang L; Li YH; Shi YX; Lin TY; Han B; Wang F; Qiu MZ; He YJ; Guan ZZ
    Chemotherapy; 2008; 54(3):228-35. PubMed ID: 18560231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of thymidine phosphorylase by interferon and taxanes occurs only in human cancer cells with low thymidine phosphorylase activity.
    Fukushima M; Okabe H; Takechi T; Ichikawa W; Hirayama R
    Cancer Lett; 2002 Dec; 187(1-2):103-10. PubMed ID: 12359357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomodulation of 5-fluorouracil by interferon-alpha in human renal carcinoma cells: relationship to the expression of thymidine phosphorylase.
    Morita T; Tokue A
    Cancer Chemother Pharmacol; 1999; 44(2):91-6. PubMed ID: 10412941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-Ethoxy-2'-deoxyuridine, a novel substrate for thymidine phosphorylase, potentiates the antitumor activity of 5-fluorouracil when used in combination with interferon, an inducer of thymidine phosphorylase expression.
    Schwartz EL; Baptiste N; Megati S; Wadler S; Otter BA
    Cancer Res; 1995 Aug; 55(16):3543-50. PubMed ID: 7627962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double 5-fluorouracil modulation with folinic acid and recombinant alpha-2B-interferon. A phase I-II study in metastatic colorectal cancer patients.
    Brunetti I; Falcone A; Bertuccelli M; Cianci C; Ricci S; Conte PF
    Am J Clin Oncol; 1994 Jun; 17(3):210-4. PubMed ID: 8192103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus enteritis after treatment with 5-fluorouracil, leukovorin, cisplatin, and alpha-interferon.
    Theodossiou C; Temeck B; Vargas H; Yang J; Vargas M; Hahn S; Pass H
    Am J Gastroenterol; 1995 Jul; 90(7):1174-6. PubMed ID: 7611225
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.